
PYC Therapeutics Ltd
ASX:PYC

Intrinsic Value
The intrinsic value of one
PYC
stock under the Base Case scenario is
0.56
AUD.
Compared to the current market price of 1.2 AUD,
PYC Therapeutics Ltd
is
Overvalued by 54%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
PYC Therapeutics Ltd
Fundamental Analysis

PYC Therapeutics’ valuation hinges on the success of its lead candidate targeting inherited retinal diseases, and any setback in clinical trials could severely diminish investor confidence and heighten the company’s cash burn rate.
PYC Therapeutics’ precision RNA platform has shown promising preclinical data that could pave the way for a breakthrough therapy in inherited retinal diseases, unlocking substantial market potential for targeted treatments.

Revenue & Expenses Breakdown
PYC Therapeutics Ltd
Balance Sheet Decomposition
PYC Therapeutics Ltd
Current Assets | 62.1m |
Cash & Short-Term Investments | 49.3m |
Receivables | 12.3m |
Other Current Assets | 605.5k |
Non-Current Assets | 6.1m |
PP&E | 2.2m |
Intangibles | 4m |
Free Cash Flow Analysis
PYC Therapeutics Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
PYC Therapeutics Ltd
Revenue
|
26.4m
AUD
|
Operating Expenses
|
-75m
AUD
|
Operating Income
|
-48.5m
AUD
|
Other Expenses
|
332.1k
AUD
|
Net Income
|
-48.2m
AUD
|
PYC Profitability Score
Profitability Due Diligence
PYC Therapeutics Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Score
PYC Therapeutics Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
PYC Solvency Score
Solvency Due Diligence
PYC Therapeutics Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Score
PYC Therapeutics Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PYC Price Targets Summary
PYC Therapeutics Ltd
According to Wall Street analysts, the average 1-year price target for
PYC
is 3.48 AUD
with a low forecast of 2.32 AUD and a high forecast of 5.01 AUD.
Dividends
Current shareholder yield for PYC is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
PYC
stock under the Base Case scenario is
0.56
AUD.
Compared to the current market price of 1.2 AUD,
PYC Therapeutics Ltd
is
Overvalued by 54%.